Αποτελέσματα Αναζήτησης
3 Μαρ 2020 · The World Health Organization has advised reduction of sugar intake to avoid chronic diseases such as fatty liver disease, T2DM, and metabolic disorders.36,37 Despite great concern about the metabolic risks of added sugar, consumption of SSBs is steadily increasing, especially among younger people.4 In addition, people tend to consume diverse ...
- Open in a Separate Window
Growing evidence suggests links between sugar-sweetened...
- Open in a Separate Window
Too much sugar can cause obesity, and being obese is a contributing factor for liver disease. In fact, non-alcohol related fatty liver disease (NAFLD) is likely to overtake alcohol as the leading caused of liver disease in the next few years (1).
Dietary sugars in the gut can alter the microbiome, increasing endotoxin that promotes hepatic IR. 30 Monosaccharides enter the liver, and fructose is metabolized into fructose-1-P and further into acetyl-CoA, fueling DNL. 12 Fructose, glucose, and insulin activate ChREBP & SREBP-1c, which transcriptionally activates genes in DNL.
Key point. Fructose causes fatty liver through the general activation of lipogenesis and blocking of fatty acid oxidation. The discovery of NAFLD and its association with metabolic syndrome. The association of diabetes with liver disease and gout has been known for over 120 years 18 and is strongly associated with insulin resistance.
6 Ιαν 2022 · "The effects of added sugar intake — higher blood pressure, inflammation, weight gain, diabetes, and fatty liver disease — are all linked to an increased risk for heart attack and stroke," says Dr. Hu.
15 Ιαν 2013 · In trials of adults with ad libitum diets (that is, with no strict control of food intake), reduced intake of dietary sugars was associated with a decrease in body weight (0.80 kg, 95% confidence interval 0.39 to 1.21; P<0.001); increased sugars intake was associated with a comparable weight increase (0.75 kg, 0.30 to 1.19; P=0.001).
8 Ιουν 2022 · Introduction. Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in Western countries. Its incidence is expected to keep growing, parallel to the incidence of metabolic syndrome (MetS) and its determinants.
